"Promising Results: Argenx Drug Slows Nerve Disorder Progression"

Belgian drugmaker Argenx announced that its antibody treatment, Vyvgart, significantly delayed the progression of chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune nerve disorder that causes loss of feeling and muscle strength in the arms and legs. In a Phase 3 clinical trial, Vyvgart demonstrated a 61% reduction in the risk of relapse compared to a placebo, achieving the trial's main goal.